乙型肝炎表面抗原血清清除：免疫机制，临床影响，药物开

StephenW

Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development

    Issam Tout
    Dimitri Loureiro
    Abdellah Mansouri
    Vassili Soumelis
    Nathalie Boyer
    Tarik Asselah

Published:April 22, 2020DOI:https://doi.org/10.1016/j.jhep.2020.04.013
PlumX Metrics

    Summary
    Keywords
    Introduction
    Molecular virology and structure of HBsAg
    HBsAg detection and quantification
    HBsAg seroclearance: prevalence and clinical significance
    Immune cells and HBsAg
    Innate immune cells
    Adaptive immune cells
    Cytokines and HBsAg
    TLRs and HBsAg
    HBsAg seroclearance in animal models
    HBsAg seroclearance and current therapies
    HBsAg seroclearance and novel therapies
    Conclusion
    Financial support
    Authors' contributions
    Conflict of interest
    Supplementary data
    References
    Article Info
    Figures
    Tables
    Related Articles

Summary
HBsAg seroclearance occurs rarely in the natural history of chronic hepatitis B (CHB) infection and is associated with improved clinical outcomes. Many factors are associated with HBsAg seroconversion, including immune and viral factors. However, the immune mechanisms associated with HBsAg seroclearance are still difficult to elucidate. HBsAg seroclearance is the ideal aim of HBV treatment. Unfortunately, this goal is rarely achieved with current treatments. Understanding the mechanisms of HBsAg loss appears to be important for the development of curative HBV treatments. While studies from animal models give insights into the potential immune mechanisms and interactions occurring between the immune system and HBsAg, they do not recapitulate all features of CHB in humans and are subject to variability due to their complexity. In this article, we review recent studies on these immune factors, focusing on their influence on CHB progression and HBsAg seroconversion. These data provide new insights for the development of therapeutic approaches to partially restore the anti-HBV immune response. Targeting HBsAg will ideally relieve the immunosuppressive effects on the immune system and help to restore anti-HBV immune responses.
Keywords

    Chronic HBV infection
    HBsAg seroclearance
    Immune system
    Interferon
    Nucleos(t)ide analogues
    HBV therapy

StephenW

乙型肝炎表面抗原血清清除：免疫机制，临床影响，药物开发的重要性

    伊萨姆·图特（Issam Tout）
    迪米特里·洛雷罗（Dimitri Loureiro）
    阿卜杜拉·曼苏里（Abdellah Mansouri）
    瓦西里·苏梅利斯（Vassili Soumelis）
    娜塔莉·博耶（Nathalie Boyer）
    塔里克·阿瑟拉（Tarik Asselah）

发布时间：2020年4月22日DOI：https：//doi.org/10.1016/j.jhep.2020.04.013
PlumX指标


摘要
HBsAg血清清除在慢性乙型肝炎（CHB）感染的自然史中很少发生，并且与改善的临床结果相关。 HBsAg血清转化与许多因素有关，包括免疫和病毒因素。但是，与HBsAg血清清除相关的免疫机制仍然难以阐明。 HBsAg血清清除是HBV治疗的理想目标。不幸的是，目前的治疗很少达到这个目标。了解HBsAg丢失的机制对于开发治疗性HBV治疗似乎很重要。虽然动物模型的研究可以洞悉潜在的免疫机制和免疫系统与HBsAg之间发生的相互作用，但它们不能概括人类CHB的所有特征，并且由于其复杂性而易变。在本文中，我们回顾了有关这些免疫因子的最新研究，重点是它们对CHB进展和HBsAg血清转化的影响。这些数据为开发可部分恢复抗HBV免疫反应的治疗方法提供了新的见解。靶向HBsAg将理想地减轻对免疫系统的免疫抑制作用，并有助于恢复抗HBV免疫反应。
关键词

    慢性HBV感染
    HBsAg血清清除
    免疫系统
    干扰素
    核苷类似物
    乙肝病毒治疗

StephenW

https://www.journal-of-hepatolog ... 20)30225-7/fulltext